Pfenex receives $143.5m contract to develop new anthrax vaccine

US-based Pfenex has received a $143.5m five-year contract from the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS) to advance development of Px563L, a mutant recombinant protective a…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news